Initial Public Offering

Initial Public Offering


Baird served as a co-manager in this offering


NewLink Genetics Corporation (NASDAQ-GM: NLNK) (“NewLink” or the “Company”) recently completed an initial public offering of 6,200,000 shares of its common stock at a price of $7.00 per share, generating gross proceeds of approximately $43.4 million. The Company intends to use the net proceeds from this offering to fund clinical trials and other research and development activities for its product candidates and for working capital and other general corporate purposes.

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The Company’s portfolio of biologic and small-molecule immunotherapy product candidates is intended to treat a wide range of oncology indications. NewLink’s lead product candidate, HyperAcute Pancreas, is in a Phase 3 clinical trial in surgically resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (“SPA”) with the FDA. To date, the Company’s HyperAcute product candidates have been used in more than 200 patients and have demonstrated a favorable safety profile. In addition to the HyperAcute candidates, NewLink is researching and developing new drugs capable of breaking the immune system’s tolerance to cancer.

For additional information about this transaction, please contact:

Ryan Mausehund (650) 858-3817
Travis Lacey (312) 609-4935
Initial Public Offering
November 2011
NewLink Genetics Corporation
Target Location
North America